| Aug 7 |
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Aug 6 |
Catalyst Pharmaceuticals Q2 2024 Earnings Preview
|
| Jul 30 |
Top 3 Health Care Stocks You May Want To Dump This Quarter
|
| Jul 24 |
Catalyst sells Canadian rights to Duchenne drug to Kye Pharma
|
| Jul 24 |
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
|
| Jul 22 |
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
|
| Jul 6 |
Catalyst Pharmaceuticals: New Products In Proving Phase
|
| Jun 7 |
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
|
| Jun 7 |
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Been Rising: Are Strong Financials Guiding The Market?
|
| May 30 |
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
|
